GlassScriptPhysician profile
Brian G Wilson
NPI 1760433247
$11,305.59
in general payments reported to CMS, 2019-2025
35 companies · $1,790 in 2025
The $1,790 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $1,283 · 2021: $1,516 · 2022: $1,665 · 2023: $1,634 · 2024: $2,047 · 2025: $1,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,245 · Education: $139 · Consulting Fee: $86.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,245.02 |
| Education | $139.27 |
| Consulting Fee | $86.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,866.86 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,635.41 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,014.74 | 2020-2025 | Cuvitru, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $993.37 | 2019-2025 | Dupixent |
| Csl Behring | $780.27 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $635.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $575.95 | 2019-2025 | |
| Pfizer INC. | $446.22 | 2019-2024 | |
| Genentech USA, INC. | $433.73 | 2020-2025 | Xolair |
| Amgen INC. | $323.38 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $300.30 | 2021-2025 | Xembify |
| Kaleo, INC. | $298.76 | 2019-2022 | |
| Pharming Healthcare, INC. | $281.91 | 2019-2025 | Ruconest |
| Octapharma USA, INC. | $245.10 | 2020-2024 | Cutaquig |
| Biocryst US Sales Co., LLC | $196.65 | 2022-2025 | Orladeyo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $121.56 | 2019-2022 | |
| Shire North American Group INC | $106.50 | 2019 | |
| Adma Biomanufacturing LLC | $102.11 | 2021-2024 | |
| Leo Pharma INC. | $99.24 | 2022-2025 | Adbry, Anzupgo |
| Optinose US, INC. | $80.71 | 2019-2020 | |
| Ionis Pharmaceuticals, INC. | $80.53 | 2025 | Dawnzera |
| Horizon Therapeutics Plc | $77.76 | 2023 | Actimmune |
| Teva Pharmaceuticals USA, INC. | $77.31 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $66.40 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $65.37 | 2021 | |
| Incyte Corporation | $62.90 | 2022 | |
| Blueprint Medicines Corporation | $57.68 | 2023-2024 | Ayvakit |
| Aimmune Therapeutics, INC. | $57.29 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $51.34 | 2024-2025 | Ryaltris |
| Lilly USA, LLC | $47.27 | 2025 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $41.76 | 2025 | Neffy |
| Abbvie INC. | $26.32 | 2023 | Rinvoq |
| Paratek Pharmaceuticals, INC. | $23.00 | 2025 | Xhance |
| Biocryst Pharmaceuticals, INC. | $20.17 | 2020 | |
| Circassia INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.